Verucerfont 是促肾上腺皮质激素释放因子受体 1 (CRF1) 的拮抗剂，对于 CRF1，CRF2 和 CRF-BP 的 IC₅₀ 值分别为 6.1，>1000 和 >1000 nM。

Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC 50 s of ~6.1, >1000 and >1000?nM for CRF1, CRF2, and CRF-BP, respectively.

Solid

IC50: 6.1 nM (CRF1), >1000 nM (CRF2), >1000 nM (CRF-BP)

Post hoc analysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316?311, and pexacerfont (P<0.001 for all comparisons collapse across time-points); the latter three treatments in turn do not differ from each other. A differential effect of treatments over time is also shown by a significant treatment×time interaction (F[20,140]=6.4, P<0.001). Accordingly, detailed Post hoc analysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6?h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline). has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Schwandt ML, et al. The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects. Neuropsychopharmacology. 2016 Nov;41(12):2818-2829.

In Vitro: DMSO : 83.33 mg/mL (205.00 mM; Need ultrasonic)配制储备液